BioSpace News Archive

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP).

Anthropogenic activities have led to increased amounts of mercury being discharged into aquatic systems, where it accumulates in fish as methylmercury, an organic form of mercury that is neurotoxic.

NEOGEN® Corporation and Gencove, the leading low-pass whole genome sequencing and analysis software company, announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis.

Accumulus Synergy, a nonprofit organization working to develop an information and data exchange platform aimed at transforming how drug innovators and health authorities worldwide interact, today announced AstraZeneca (LSE/STO/Nasdaq: AZN) has joined Accumulus Synergy as a sponsor company.

BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery systems for neurodegenerative diseases.

Suvoda LLC, today announced they have entered into an agreement to partner with N-SIDE — a deeptech company that empowers organizations in the clinical trials industry to make better decisions and optimize the use of critical resources. 

Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability (CIN) as a vulnerability for cancer cells, today announced that members of its management team are scheduled to participate in a fireside chat at the 2022 Guggenheim Synthetic Lethality Day on May 16th at 11:30 a.m. ET.

Bristol Myers Squibb (NYSE: BMY) today announced two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis.

Rapid Dose Therapeutics Provides Shareholder Update Regarding Vaccine Collaboration Agreement with Oakland Health Limited in the United Kingdom.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.